Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 9/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18269353 | 0.84 | ERN1 (0.49) | ERN1METPDK2LRRK2MAPK1 | |
| SCHEMBL21557014 | 0.83 | LRRK2 (0.55) | ERN1METLRRK2MAPK1 | |
| SCHEMBL18269354 | 0.80 | ERN1 (0.46) | ERN1METPDK2LRRK2MAPK1 | |
| SCHEMBL24922493 | 0.80 | PIK3CA (0.46) | ERN1METPDK2LRRK2 | |
| SCHEMBL2698114 | 0.79 | ERN1 (0.45) | ERN1METLRRK2MAPK1ALOX5AP | |
| SCHEMBL29516367 | 0.79 | RET (0.58) | METALOX5APFEN1CHRM1 | |
| SCHEMBL19998604 | 0.78 | ERN1 (0.56) | ERN1LRRK2ALOX5APFEN1CHRM1 | |
| SCHEMBL29870077 | 0.74 | MET (0.46) | METALK | |
| SCHEMBL17809710 | 0.74 | ERN1 (0.52) | ERN1METPDK2ALOX5APFEN1 | |
| SCHEMBL13036109 | 0.74 | KCNH2 (0.59) | ERN1ALOX5APFEN1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567040-B1 | METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES | AMGEN INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3567040-B1 | METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES | AMGEN INC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3567040-A1 | METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES | Amgen, Inc (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3567040-A1 | METHOD FOR THE PREPARATION OF INTERMEDIATES USEFUL FOR THE SYNTHESIS OF [1,2,4]-TRIAZOLO[4,3-A]PYRIDINES | Amgen, Inc (US) | 2019-11-13 | — | — | EP | disclosed |
| EP-3013825-B1 | METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES | AMGEN INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3013825-B1 | METHOD FOR THE PREPARATION OF (1,2,4)-TRIAZOLO(4,3-A)PYRIDINES | AMGEN INC (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-2995618-B1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2995618-B1 | [1,2,4]TRIAZOL [4,3-A]PYRIDINE DERIVATE, PREPARATION METHOD THEREFOR OR MEDICAL APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTD (CN) | 2019-01-09 | — | — | EP | disclosed |
| EP-2755976-B1 | 6-SUBSTITUTED 3-(QUINOLIN-6-YLTHIO)-[1,2,4]TRIAZOLO[4,3-A]PYRIDINES AS C-MET TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2018-07-18 | — | — | EP | disclosed |
| EP-2231663-B1 | 6-([1,2,4]TRIAZOLO[4,3-A]PYRIDIN-3-YLMETHYL)-1,6-NAPHTHYRIDIN-5(6H)-ONE DERIVATIVES AS C-MET INHIBITORS | AMGEN INC (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| EP-2231663-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE AS C-MET INHIBITORS | Amgen, Inc (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009091374-A2 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ERN1 3793/4885MET 3/4885PDK2 1182/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | ERN1 3793/4885MET 3/4885PDK2 1182/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | ERN1 3793/4885MET 3/4885PDK2 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.